Last reviewed · How we verify

Ketamine + magnesium

University of Chile · FDA-approved active Small molecule

Ketamine + magnesium is a NMDA receptor antagonist combination Small molecule drug developed by University of Chile. It is currently FDA-approved for Treatment-resistant depression, Acute suicidality, Chronic pain conditions. Also known as: ketalar + Magnesium Sulfate.

Ketamine blocks NMDA receptors while magnesium enhances this blockade and stabilizes the drug's effects, together producing rapid-onset antidepressant and analgesic effects.

Ketamine blocks NMDA receptors while magnesium enhances this blockade and stabilizes the drug's effects, together producing rapid-onset antidepressant and analgesic effects. Used for Treatment-resistant depression, Acute suicidality, Chronic pain conditions.

At a glance

Generic nameKetamine + magnesium
Also known asketalar + Magnesium Sulfate
SponsorUniversity of Chile
Drug classNMDA receptor antagonist combination
TargetNMDA receptor
ModalitySmall molecule
Therapeutic areaPsychiatry, Pain Management
PhaseFDA-approved

Mechanism of action

Ketamine is a non-competitive NMDA receptor antagonist that produces dissociative anesthesia and has been shown to have rapid antidepressant properties. Magnesium acts as a natural NMDA receptor antagonist and may potentiate ketamine's effects while potentially reducing dissociative side effects and improving tolerability. The combination is hypothesized to provide synergistic neuroprotection and faster therapeutic onset.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ketamine + magnesium

What is Ketamine + magnesium?

Ketamine + magnesium is a NMDA receptor antagonist combination drug developed by University of Chile, indicated for Treatment-resistant depression, Acute suicidality, Chronic pain conditions.

How does Ketamine + magnesium work?

Ketamine blocks NMDA receptors while magnesium enhances this blockade and stabilizes the drug's effects, together producing rapid-onset antidepressant and analgesic effects.

What is Ketamine + magnesium used for?

Ketamine + magnesium is indicated for Treatment-resistant depression, Acute suicidality, Chronic pain conditions.

Who makes Ketamine + magnesium?

Ketamine + magnesium is developed and marketed by University of Chile (see full University of Chile pipeline at /company/university-of-chile).

Is Ketamine + magnesium also known as anything else?

Ketamine + magnesium is also known as ketalar + Magnesium Sulfate.

What drug class is Ketamine + magnesium in?

Ketamine + magnesium belongs to the NMDA receptor antagonist combination class. See all NMDA receptor antagonist combination drugs at /class/nmda-receptor-antagonist-combination.

What development phase is Ketamine + magnesium in?

Ketamine + magnesium is FDA-approved (marketed).

What are the side effects of Ketamine + magnesium?

Common side effects of Ketamine + magnesium include Dissociation, Dizziness, Nausea, Increased blood pressure, Sedation.

What does Ketamine + magnesium target?

Ketamine + magnesium targets NMDA receptor and is a NMDA receptor antagonist combination.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing